Intra-Cellular Therapies (ITCI) currently reports a ROE of -6.5%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Intra-Cellular Therapies's ROE history and peer comparisons.

Intra-Cellular Therapies's ROE of -6.5% is lower than the Healthcare sector average of 20.86%. That is roughly 131.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Intra-Cellular Therapies's current -6.5% should be judged against Healthcare norms (sector average: 20.86%) and against ITCI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -6.5%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Intra-Cellular Therapies, and consider following ITCI for alerts when major investors trade the stock.

Intra-Cellular Therapies is classified in the Healthcare sector. On ROE, it currently shows -6.5% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ITCI with unrelated industries.